Citations

Clear

313 citation(s) found for "Alvarez, P".

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
Luo, Xi , Feurstein, Simone , Mohan, Shruthi , Jackson, Sarah A. , Keel, Sioḃán , Chicka, Michael C., Brown, Anna , Agarwal, Anupriya , Luo, Minjie , Li, Zejuan , Ross, Justyne , Pineda‐Alvarez, Daniel , Bertuch, Alison A. , Mehta, Nikita , Vulliamy, Tom, Wang, Ying , Nichols, Kim E. , Malcovati, Luca , Walsh, Michael F. , Rawlings, Lesley , Soulier, Jean , Raimbault, Anna , Zhang, Liying , Ryan, Gabriella, Speck, Nancy A. , Wu, David , Godley, Lucy A. , Malcovati, Luca , Godley, Lucy A , Brown, Anna L , Jackson, Sarah A , Nichols, Kim E , Porter, Christopher C. , Kesserwan, Chimene A. , Baliakas, Panagiotis , DiNardo, Courtney D. , McWeeney, Shannon K. , Routbort, Mark J. , Ryan, Gabriella, Plon, Sharon E.

Mayo Clinic

Blood Advances | October 16, 2019 | Volume: 3 | Issue: 20 | Pages: 2962-2979

10.1182/bloodadvances.2019000644 | PMID 31648317 Get It

Key Points The ClinGen MM-VCEP has specified RUNX1-specific curation rules to address gene function, gene-specific domains, and phenotypic criteria. RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the need for expert variant curation.
Evaluation of a novel technique involving ultrasound-guided, temporary, percutaneous gastropexy and gastrostomy catheter placement for providing sustained gastric decompression in dogs with gastric dilatation-volvulus
Fox‐Alvarez, W. Alexander, Case, Jennifer, Joyce, Ashley C., Cooke, Kirsten L. , Toskich, Beau B. , Case, J. Brad, Lewis, Daniel Dean

Mayo Clinic

Journal of the American Veterinary Medical Association | October 16, 2019 | Volume: 255 | Issue: 9 | Pages: 1027-1034

10.2460/javma.255.9.1027 | PMID 31617809 Get It

Abstract OBJECTIVE To evaluate the feasibility of ultrasound-guided, temporary, percutaneous T-fastener gastropexy (TG) and gastrostomy catheter (GC) placement for providing sustained gastric decompression in dogs with acute gastric dilatation-volvulus (GDV) and to compare findings with those of trocarization. ANIMALS 16 dogs with GDV. PROCEDURES Dogs were randomly assigned to undergo gastric decompression by means of percutaneous trocarization (trocar group; n = 8) or temporary TG and GC placement (TTG+GC group; 8) with ultrasound guidance. The gastric volvulus was then surgically corrected, and the decompression sites were examined. Outcomes were compared between groups. RESULTS The proportion of dogs with successful decompression did not differ significantly between the TTG+GC (6/8) and trocar (7/8) groups; median procedure duration was 3.3 and 3.7 minutes, respectively. After the failed attempts in the TTG+GC group, the procedure was modified to include ultrasound guidance during T-fastener placement. The decrease in intragastric pressure by 5 minutes after trocar or GC insertion was similar between groups. For dogs in the TTG+GC group, no significant difference in intragastric pressure was identified between 5 and 60 minutes after GC insertion. Complications included inadvertent splenic or jejunal placement in 2 dogs (TTG+GC group) and malpositioned and ineffective trocar placement in 1 dog (trocar group). All dogs survived for at least 2 weeks. CONCLUSIONS AND CLINICAL RELEVANCE Ultrasound-guided, temporary, percutaneous TG and GC placement was safe and effective at providing sustained gastric decompression in dogs with GDV, suggesting that this technique would be ideal for dogs in which surgical delays are anticipated or unavoidable.
A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients
Renzo, Nicola Di , Vincelli, Iolanda Donatella , Matis, Serena , Musolino, Caterina , Vigna, Ernesto , Levato, Luciano , Angrilli, F., Consoli, Ugo , Festini, Gianluca, Longo, Giuseppe, Arcari, Annalisa , Mannina, Donato , Gentile, Massimo , Shanafelt, Tait D. , Cutrona, Giovanna , Molica, Stefano , Tripepi, Giovanni Luigi , Alvarez, Isabel, Mauro, Francesca Romana , Raimondo, Francesco Di , Todoerti, Katia , Fabris, Sonia Maria , Zupo, Simona , Cortelezzi, Agostino , Federico, Massimo , Recchia, Anna Grazia , Kay, Neil E. , Ferrarini, Manlio , Neri, Antonino , Morabito, Fortunato

Mayo Clinic

Blood | October 12, 2019 | Volume: 126 | Issue: 23 | Pages: 2930-2930

10.1182/blood.v126.23.2930.2930 Get It

Abstract Background: Over the last two decades several phenotypic, molecular, and chromosomal markers have been identified that are significantly associated with the prognosis of CLL patients. Therefore, clinicians managing CLL patients would benefit from a simplified prognostic index. Methods: We analyzed prospectively collected data from 337 Binet A CLL patients enrolled in Italian the O-CLL1-GISL protocol with the aim of developing scores capable of predicting treatment free survival (TFS). Factors independently associated with TFS were included in the prognostic indexes. To account for differences in the magnitude of the association between the individual independent factors and TFS, we assigned a weighted risk score to each factor based on ranges of their corresponding hazard ratios (HRs) (i.e., 1 point for HR 1.1-1.9; 2 points for HR 2.0-2.9, etc.). The total risk score was then calculated by the sum of the ratings of each factor on individual basis. Risk groups were identified combining risk categories with a non-statistically different TFS. Results: We developed two scores based on weighted multivariable models: the first included clinical and laboratory parameters [clinical score (c-score)], while the second was based on biological markers [biological score (b-score)] (Table 1). The c-score allowed to predict the TFS of patients through the combination of Rai stage, b2-microglobulin and absolute lymphocyte count (ALC), while the b-score predicted TFS by IGHV mutational status and CD38 expression. The c-score showed a C-statistic of 0.72, while the b-score was 0.67, although cases stratified according to the b-score showed a more specific mRNA/microRNA profile. When the two scores were forced in a multivariate analysis, both showed an independent predictive value on TFS with a similar HR, demonstrating their complementarity. Thus, we attempted to integrate the two scores performing a further multivariate analysis in which all parameters, significantly associated with TFS at univariate analysis, were tested (Table 1). ALC, Rai stage, b2-microglobulin together with IGHV mutational status, resulted independently associated with TFS. We constructed a weighted score [comprehensive score (co-score)], including all the above 4 variables, which allowed the identification of 3 different risk groups with significantly different TFS (Figure 1). The C-statistic of the g-score was 0.75, showing a better concordance than the other two scores. Moreover, its validity was externally validated in a series of 297 newly diagnosed Binet A CLL patients from the Mayo Clinic, USA. Conclusions: Using this multistep process and external validation, we developed a score with high discriminatory power and predictive significance on the individual patient level. Table 1. Univariate and multivariate Cox proportional Hazards Models Variable Univariate analysis Multivariate analysis Clinical model Biological model Comprehensive model HR (95% CI) P HR (95% CI) P score HR (95% CI) P score HR (95% CI) P score Age (years) <60/>60 1.12 (0.73-1.74) 0.59 - - - - - - - - - Sex Male/Female 0.93 (0.6-1.44) 0.93 - - - - - - - - - Rai stage 0/I-II 2.30 (1.47-3.50) <0.0001 2.13 (1.24-3.03) 0.004 0/2 - - - 1.76 (1.11-2.78) 0.015 0/1 ALC (109/L) <10/>10 3.43 (1.99-5.92) <0.0001 2.91 (1.85-5.20) <0.0001 0/2 - - - 2.70 (1.54-4.72) 0.001 0/2 b-2 microglobulin normal/elevated 3.04 (1.96-4.70) <0.0001 2.78 (1.79-4.30) <0.0001 0/2 - - - 2.65 (1.66-4.21) <0.0001 0/2 LDH normal/elevated 1.25 (0.57-2.71) 0.57 - - - - - - - - - CD38 negative/positive 3.22 (2.06-5.02) <0.0001 - - - 2.11 (1.15-3.16) 0.02 0/2 1.40 (0.80-2.42) 0.24 - ZAP-70 negative/positive 2.34 (1.51-3.61) <0.0001 - - - 1.21 (0.70-2.16) 0.485 - 1.0 (0.98-1.01) 0.72 - IGHV mutated/unmutated 3.57 (2.32-5.50) <0.0001 - - - 2.10 (1.12-3.90) 0.019 0/2 2.39 (1.27-4.50) 0.007 0/2 FISH risk low+int/high 2.93 (1.46-5.90) 0.002 - - - 1.65 (0.76-3.34) 0.216 - 1.80 (0.84-3.88) 0.13 - Abbreviations: ALC: absolute lymphocyte count; CI: confidential interval; HR: hazard ratio. Figure 1. TFS according to comprehensive progression risk score. Figure 1. TFS according to comprehensive progression risk score. Disclosures Shanafelt: Cephalon: Research Funding; Glaxo-Smith-Kline: Research Funding; Genentech: Research Funding; Hospira: Research Funding; Celgene: Research Funding; Jannsen: Research Funding; Polyphenon E International: Research Funding; Pharmacyclics: Research Funding. Kay:Genentech: Research Funding; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; Hospira: Research Funding; Tolero Pharma: Research Funding; Pharmacyclics: Research Funding.
Widespread and Dynamic Translational Control of Red Blood Cell Development
Zhang, Xu , Alvarez-Dominguez, Juan, Hu, Wenqian

Mayo Clinic

Blood | October 11, 2019 | Volume: 128 | Issue: 22 | Pages: 1260-1260

10.1182/blood.v128.22.1260.1260 Get It

Abstract Cell development requires tight yet dynamic control of protein production. Here, we use murine erythropoiesis as a model to study translational regulatory dynamics during mammalian cell differentiation. We uncover pervasive translational control of protein synthesis, including widespread alternative translation initiation and termination, stoichiometric synthesis, and dynamic use of upstream reading frames. In addition, we identify hundreds of mRNAs with dynamic translation efficiencies during erythropoiesis. Interestingly, these mRNAs have significantly enriched binding motifs of many mRNA-binding proteins that are expressed with high specificity in hematopoietic cells, suggesting that those mRNA-binding proteins are important players in the translational regulatory programs in erythropoiesis. A major such program involves enhanced decoding of specific mRNAs depleted in terminally differentiating/enucleating cells with decreasing transcriptional capacity. We functionally characterized one such protein, Rbm38, which was previously identified as a splicing factor in terminal erythropoiesis, can enhance the translation of a subset of those mRNAs by interacting with the general translation initiation factor eIF4G in erythroid cells. Altogether, our findings reveal widespread and dynamic translational control in supporting specialized mammalian cell formation. Disclosures No relevant conflicts of interest to declare.
Successful lung transplantation from a donor with lung and ovarian masses
Asif, Abuzar A. , Narula, Tathagat , Erasmus, D , Alvarez, Francisco , Nichols, Todd A. , Jacob, Samuel , Cortese, Cherise , Makey, Ian A. , Erasmus, David B, Pham, Si M.

Mayo Clinic

Journal of Surgical Case Reports | October 8, 2019 | Volume: 2019 | Issue: 11 | Pages: No page available

10.1093/jscr/rjz307 | PMID 31719970 Get It

Abstract Declining a donor when there is a reasonable possibility that the abnormality on chest imaging could be benign carries the risk of losing out on potentially usable lungs in an already parched landscape of donor organ availability. Cautiously aggressive attitudes to acceptance of borderline donors can help bridge the significant discrepancy that exists between the demand and availability of donor organs. Herein, we present a case highlighting successful bilateral lung transplantation from a relatively imperfect donor.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.
Extracorporeal Liver Support for the Treatment of Hyperammonemia After Lung Transplantation
Kwon, Minkyung , Alvarez, Francisco , Patel, Alicia, Canabal, Juan, Haddad, Tarik , Erasmus, D , Narula, Tathagat , Moreno Franco, Pablo, Canabal, Juan M, Haddad, Tarik J, Erasmus, David B, Mallea, Jorge M. , Franco, Pablo Moreno

Mayo Clinic

Transplantation | August 5, 2019 | Volume: 104 | Issue: 3 | Pages: e75-e76

10.1097/tp.0000000000002881 | PMID 31385932 Get It

Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)
Deutsch, Gary B. , Deneve, Jeremiah L. , Al-Kasspooles, Mazin F, Nfonsam, Valentine , Gunderson, Camille C., Secord, Angeles Alvarez , Rodgers, Phillip , Hendren, Samantha , Silberfein, Eric J. , Grant, Marcia , Sloan, Jeff A. , Arnold, Kathryn B. , Sloan, Jeff, Sun, Virginia Chih-Yi , Anderson, Garnet L. , Krouse, Robert S.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | May 24, 2019 | Volume: 37 | Issue: 1 | Pages: 12-18

10.1177/1049909119851471 | PMID 31122027 Get It

Background: Prospective, randomized trials are needed to determine optimal treatment approaches for palliative care problems such as malignant bowel obstruction (MBO). Randomization poses unique issues for such studies, especially with divergent treatment approaches and varying levels of equipoise. We report our experience accruing randomized patients to the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (SWOG S1316) study, comparing surgical and nonsurgical management of MBO. Methods: Patients with MBO who were surgical candidates and had treatment equipoise were accrued and offered randomization to surgical or nonsurgical management. Patients choosing nonrandomization were offered prospective observation. Trial details are listed on www.clinicaltrials.gov (NCT #02270450). An accrual algorithm was developed to enhance enrollment. Results: Accrual is ongoing with 176 patients enrolled. Most (89%) patients chose nonrandomization, opting for nonsurgical management. Of 25 sites that have accrued to this study, 6 enrolled patients on the randomization arm. Approximately 59% (20/34) of the randomization accrual goal has been achieved. Patient-related factors and clinician bias have been the most prevalent reasons for lack of randomization. An algorithm was developed from clinician experience to aid randomization. Using principles in this tool, repeated physician conversations discussing treatment options and goals of care, and a supportive team–approach has helped increase accrual. Conclusions: Experience gained from the S1316 study can aid future palliative care trials. Although difficult, it is possible to randomize patients to palliative studies by giving clinicians clear recommendations utilizing an algorithm of conversation, allotment of necessary time to discuss the trial, and encouragement to overcome internal bias.
Does community engaged Carnegie status matter for county health rankings in the United States?
Apatu, Emma , Stallings‐Smith, Sericea , Anderson, Laura N. , Spaulding, Aaron , Spaulding, Aaron , Anderson, Laura , Álvarez, Elizabeth

Mayo Clinic

Journal of Public Health | May 21, 2019 | Volume: 43 | Issue: 1 | Pages: 164-171

10.1093/pubmed/fdz066 | PMID 31211380 Get It

Abstract Background Community engagement is commonly used to address social inequities. The Carnegie Foundation offers an optional designation for which U.S. colleges and universities may apply to facilitate better educational outcomes through the institutionalization of community engagement. This study is the first to examine the relationship between Carnegie community engaged status and community health outcomes. Methods Ordinal logistic regression was conducted to investigate the association between the presence of a community engaged institution and county health outcomes, including health behaviors, clinical care relating to access and quality, social and economic factors, and physical environment from the 2016 Robert Wood Johnson County Health Rankings and 2015 New England Resource Center for Higher Education Community engaged list. We examined 820 U.S. counties containing a university or college, 240 of which had a community engaged designation. Results Findings indicated that the presence of a community-engaged institution was positively associated with Clinical Care (OR = 1.99; 95% CI: 1.09, 3.64). Other county health factors were not similarly associated. Conclusions Our findings suggest that community engagement status may be most relevant for achieving better access and quality of clinical care. More research is needed to explore this association in the U.S. and internationally.
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).
Attia, Steven , Conry, Robert M. , Sankhala, Kamalesh K. , Seon, Ben K. , Alvarez, Delia, Adams, Bonne J., Theuer, Charles P. , Riedel, Richard F. , Robinson, Steven I. , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10514-10514

10.1200/jco.2015.33.15_suppl.10514 Get It